Acetylcystein

DRUG2 trials

Sponsors

University of Leipzig, University Hospital, Strasbourg, France

Conditions

Ischaemia-reperfusion InjuryMyocardial Infarction

Phase 3

Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein

CompletedNCT00463749

University of LeipzigMyocardial Infarction

Start: 2006-12-31End: 2008-06-30Updated: 2008-07-08

Ischaemia-réperfusion During the Coronary Surgery With Beating Heart

University Hospital, Strasbourg, FranceIschaemia-reperfusion Injury

Start: 2002-06-30Target: 120Updated: 2013-01-18

Related Papers

Prognosis after ST-elevation myocardial infarction: a study on cardiac magnetic resonance imaging versus clinical routine

Trials2014-06-2555 citations

Myocardium at risk in ST-segment elevation myocardial infarction comparison of T2-weighted edema imaging with the MR-assessed endocardial surface area and validation against angiographic scoring.

2011-09-0140 citations

Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance.

2011-02-2255 citations

Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.

2010-05-01158 citations